

Jan Westerink

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/10302/publications.pdf>

Version: 2024-02-01

112
papers

1,768
citations

304743

22
h-index

345221

36
g-index

112
all docs

112
docs citations

112
times ranked

3545
citing authors

#	ARTICLE	IF	CITATIONS
1	Distribution of Estimated 10-Year Risk of Recurrent Vascular Events and Residual Risk in a Secondary Prevention Population. <i>Circulation</i> , 2016, 134, 1419-1429.	1.6	183
2	Pioglitazone and the secondary prevention of cardiovascular disease. A meta-analysis of randomized-controlled trials. <i>Cardiovascular Diabetology</i> , 2017, 16, 134.	6.8	89
3	Prevalence of Nonalcoholic Fatty Liver Disease (NAFLD) in Patients With Type 1 Diabetes Mellitus: A Systematic Review and Meta-Analysis. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, 3842-3853.	3.6	76
4	Higher Plasma Methylglyoxal Levels Are Associated With Incident Cardiovascular Disease and Mortality in Individuals With Type 2 Diabetes. <i>Diabetes Care</i> , 2018, 41, 1689-1695.	8.6	63
5	Low-grade inflammation as a risk factor for cardiovascular events and all-cause mortality in patients with type 2 diabetes. <i>Cardiovascular Diabetology</i> , 2021, 20, 220.	6.8	59
6	The relation between systemic inflammation and incident cancer in patients with stable cardiovascular disease: a cohort study. <i>European Heart Journal</i> , 2019, 40, 3901-3909.	2.2	54
7	The effect of menaquinone-7 supplementation on vascular calcification in patients with diabetes: a randomized, double-blind, placebo-controlled trial. <i>American Journal of Clinical Nutrition</i> , 2019, 110, 883-890.	4.7	53
8	Association of High Ankle Brachial Index With Incident Cardiovascular Disease and Mortality in a High-Risk Population. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2016, 36, 412-417.	2.4	45
9	Editor's Choice "Cerebral Hyperperfusion Syndrome After Carotid Artery Stenting: A Systematic Review and Meta-analysis. <i>European Journal of Vascular and Endovascular Surgery</i> , 2018, 56, 322-333.	1.5	45
10	Pharmacological and non-pharmacological interventions to influence adipose tissue function. <i>Cardiovascular Diabetology</i> , 2011, 10, 13.	6.8	43
11	Low High-Density Lipoprotein Cholesterol Is Not a Risk Factor for Recurrent Vascular Events in Patients With Vascular Disease on Intensive Lipid-Lowering Medication. <i>Journal of the American College of Cardiology</i> , 2013, 62, 1834-1841.	2.8	42
12	Magnetic resonance imaging for diagnosis of recurrent ipsilateral deep vein thrombosis. <i>Blood</i> , 2020, 135, 1377-1385.	1.4	39
13	High-dose statin monotherapy versus low-dose statin/ezetimibe combination on fasting and postprandial lipids and endothelial function in obese patients with the metabolic syndrome: The PANACEA study. <i>Atherosclerosis</i> , 2013, 227, 118-124.	0.8	38
14	The Relation Between HbA1c and Cardiovascular Events in Patients With Type 2 Diabetes With and Without Vascular Disease. <i>Diabetes Care</i> , 2015, 38, 1930-1936.	8.6	35
15	Estimating individual lifetime benefit and bleeding risk of adding rivaroxaban to aspirin for patients with stable cardiovascular disease: results from the COMPASS trial. <i>European Heart Journal</i> , 2019, 40, 3771-3778a.	2.2	34
16	Intimal and medial calcification in relation to cardiovascular risk factors. <i>PLoS ONE</i> , 2020, 15, e0235228.	2.5	34
17	Associations Between Systolic Interarm Differences in Blood Pressure and Cardiovascular Disease Outcomes and Mortality. <i>Hypertension</i> , 2021, 77, 650-661.	2.7	34
18	Autosomal dominant familial dysbetalipoproteinemia: A pathophysiological framework and practical approach to diagnosis and therapy. <i>Journal of Clinical Lipidology</i> , 2017, 11, 12-23.e1.	1.5	33

#	ARTICLE	IF	CITATIONS
19	HDL Cholesterol as a Residual Risk Factor for Vascular Events and All-Cause Mortality in Patients With Type 2 Diabetes. <i>Diabetes Care</i> , 2016, 39, 1424-1430.	8.6	31
20	Inter-arm systolic blood pressure differences, relations with future vascular events and mortality in patients with and without manifest vascular disease. <i>International Journal of Cardiology</i> , 2017, 244, 271-276.	1.7	30
21	Arterial stiffness as a risk factor for cardiovascular events and all-cause mortality in people with Type 2 diabetes. <i>Diabetic Medicine</i> , 2019, 36, 1125-1132.	2.3	30
22	Incidence of cardiovascular events and vascular interventions in patients with type 2 diabetes. <i>International Journal of Cardiology</i> , 2017, 248, 301-307.	1.7	27
23	Hemoglobin, hematocrit, and changes in cerebral blood flow: the Second Manifestations of ARterial disease-Magnetic Resonance study. <i>Neurobiology of Aging</i> , 2015, 36, 1417-1423.	3.1	24
24	The relation between healthy lifestyle changes and decrease in systemic inflammation in patients with stable cardiovascular disease. <i>Atherosclerosis</i> , 2020, 301, 37-43.	0.8	24
25	Relation between thyroid-stimulating hormone and the occurrence of cardiovascular events and mortality in patients with manifest vascular diseases. <i>European Journal of Preventive Cardiology</i> , 2012, 19, 864-873.	1.8	22
26	Plasma fibrinogen level as a potential predictor of hemorrhagic complications after catheter-directed thrombolysis for peripheral arterial occlusions. <i>Journal of Vascular Surgery</i> , 2017, 65, 1519-1527.e26.	1.1	22
27	Influence of APOE-2 genotype on the relation between adiposity and plasma lipid levels in patients with vascular disease. <i>International Journal of Obesity</i> , 2015, 39, 265-269.	3.4	21
28	The relation between thyroid-stimulating hormone and measures of adiposity in patients with manifest vascular disease. <i>European Journal of Clinical Investigation</i> , 2011, 41, 159-166.	3.4	20
29	Transcranial Doppler 24 Hours after Carotid Endarterectomy Accurately Identifies Patients Not at Risk of Cerebral Hyperperfusion Syndrome. <i>European Journal of Vascular and Endovascular Surgery</i> , 2019, 58, 320-327.	1.5	18
30	Effect of Type 2 Diabetes on Recurrent Major Cardiovascular Events for Patients With Symptomatic Vascular Disease at Different Locations. <i>Diabetes Care</i> , 2015, 38, 1528-1535.	8.6	17
31	Body Weight, Metabolic Dysfunction, and Risk of Type 2 Diabetes in Patients at High Risk for Cardiovascular Events or With Manifest Cardiovascular Disease: A Cohort Study. <i>Diabetes Care</i> , 2015, 38, 1945-1951.	8.6	17
32	The influence of baseline risk on the relation between HbA1c and risk for new cardiovascular events and mortality in patients with type 2 diabetes and symptomatic cardiovascular disease. <i>Cardiovascular Diabetology</i> , 2016, 15, 101.	6.8	17
33	Effect of Statin Therapy on Incident Type 2 Diabetes Mellitus in Patients With Clinically Manifest Vascular Disease. <i>American Journal of Cardiology</i> , 2015, 115, 441-446.	1.6	16
34	Predicting the Effect of Fenofibrate on Cardiovascular Risk for Individual Patients With Type 2 Diabetes. <i>Diabetes Care</i> , 2018, 41, 1244-1250.	8.6	16
35	Heterogeneity of Treatment Effects From an Intensive Lifestyle Weight Loss Intervention on Cardiovascular Events in Patients With Type 2 Diabetes: Data From the Look AHEAD Trial. <i>Diabetes Care</i> , 2019, 42, 1988-1994.	8.6	16
36	Tendon xanthomas: Not always familial hypercholesterolemia. <i>Journal of Clinical Lipidology</i> , 2016, 10, 1262-1265.	1.5	14

#	ARTICLE	IF	CITATIONS
37	Anticoagulant bridging in left-sided mechanical heart valve patients. <i>International Journal of Cardiology</i> , 2017, 232, 121-126.	1.7	14
38	Decline in risk of recurrent cardiovascular events in the period 1996 to 2014 partly explained by better treatment of risk factors and less subclinical atherosclerosis. <i>International Journal of Cardiology</i> , 2018, 251, 96-102.	1.7	14
39	Limited benefit of haemoglobin glycation index as risk factor for cardiovascular disease in type 2 diabetes patients. <i>Diabetes and Metabolism</i> , 2019, 45, 254-260.	2.9	14
40	Visceral Adipose Tissue and Different Measures of Adiposity in Different Severities of Diffuse Idiopathic Skeletal Hyperostosis. <i>Journal of Personalized Medicine</i> , 2021, 11, 663.	2.5	14
41	Non-alcoholic fatty liver disease: identical etiologic factors in patients with type 1 and type 2 diabetes. <i>European Journal of Internal Medicine</i> , 2022, 100, 77-82.	2.2	14
42	Metabolic consequences of adipose tissue dysfunction and not adiposity per se increase the risk of cardiovascular events and mortality in patients with type 2 diabetes. <i>International Journal of Cardiology</i> , 2016, 222, 72-77.	1.7	13
43	Mediation analysis of the relationship between type 2 diabetes and cardiovascular events and all-cause mortality: Findings from the SMART cohort. <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 1935-1943.	4.4	13
44	The relation between VLDL-cholesterol and risk of cardiovascular events in patients with manifest cardiovascular disease. <i>International Journal of Cardiology</i> , 2021, 322, 251-257.	1.7	13
45	Thyroid-stimulating hormone levels in the normal range and incident type 2 diabetes mellitus. <i>Acta Diabetologica</i> , 2019, 56, 431-440.	2.5	12
46	Predicting 10-year risk of recurrent cardiovascular events and cardiovascular interventions in patients with established cardiovascular disease: results from UCC-SMART and REACH. <i>International Journal of Cardiology</i> , 2021, 325, 140-148.	1.7	12
47	An Oral Mixed Fat Load Is Followed by a Modest Anti-inflammatory Adipocytokine Response in Overweight Patients with Metabolic Syndrome. <i>Lipids</i> , 2014, 49, 247-254.	1.7	11
48	Modifiable risk factors in adults with and without prior cardiovascular disease: findings from the Indonesian National Basic Health Research. <i>BMC Public Health</i> , 2022, 22, 660.	2.9	11
49	Chronic kidney disease and atrial fibrillation: A dangerous combination. <i>PLoS ONE</i> , 2022, 17, e0266046.	2.5	11
50	Insulin resistance and risk of vascular events, interventions and mortality in type 1 diabetes. <i>European Journal of Endocrinology</i> , 2021, 185, 831-840.	3.7	10
51	Association between CETP gene polymorphism, insulin resistance and risk of diabetes mellitus in patients with vascular disease. <i>Atherosclerosis</i> , 2015, 242, 605-610.	0.8	9
52	Intermittent pneumatic compression in combination with low-molecular weight heparin in the prevention of venous thromboembolic events in esophageal cancer surgery. <i>Journal of Surgical Oncology</i> , 2017, 115, 181-185.	1.7	9
53	The early economic evaluation of novel biomarkers to accelerate their translation into clinical applications. <i>Cost Effectiveness and Resource Allocation</i> , 2018, 16, 23.	1.5	9
54	Standardized reporting of co-morbidity outcome after bariatric surgery: low compliance with the ASMBS outcome reporting standards despite ease of use. <i>Surgery for Obesity and Related Diseases</i> , 2020, 16, 1673-1682.	1.2	9

#	ARTICLE	IF	CITATIONS
55	Cardiovascular risk factors and the risk of major adverse limb events in patients with symptomatic cardiovascular disease. <i>Heart</i> , 2020, 106, 1686-1692.	2.9	9
56	Diffuse idiopathic skeletal hyperostosis is associated with incident stroke in patients with increased cardiovascular risk. <i>Rheumatology</i> , 2022, 61, 2867-2874.	1.9	9
57	Estimated Life-Years Gained Free of New or Recurrent Major Cardiovascular Events With the Addition of Semaglutide to Standard of Care in People With Type 2 Diabetes and High Cardiovascular Risk. <i>Diabetes Care</i> , 2022, 45, 1211-1218.	8.6	9
58	Postâ€thrombotic syndrome after upper extremity deep vein thrombosis: An international Delphi consensus study. <i>Journal of Thrombosis and Haemostasis</i> , 2022, 20, 1880-1886.	3.8	9
59	Combined use of polypill components in patients with type 2 diabetes mellitus. <i>European Journal of Preventive Cardiology</i> , 2018, 25, 1523-1531.	1.8	8
60	Prediction of Lifetime and 10-Year Risk of Cancer in Individual Patients With Established Cardiovascular Disease. <i>JACC: CardioOncology</i> , 2020, 2, 400-410.	4.0	8
61	Safety of using the combination of the Wells rule and Dâ€dimer test for excluding acute recurrent ipsilateral deep vein thrombosis. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 2341-2348.	3.8	8
62	Prevalence of non-alcoholic fatty liver disease (NAFLD) and its association with surrogate markers of insulin resistance in patients with type 1 diabetes. <i>Diabetes Research and Clinical Practice</i> , 2022, 186, 109827.	2.8	8
63	Relation between adiposity and vascular events, malignancy and mortality in patients with stable cerebrovascular disease. <i>International Journal of Obesity</i> , 2017, 41, 1775-1781.	3.4	7
64	Outcomes of second opinions in general internal medicine. <i>PLoS ONE</i> , 2020, 15, e0236048.	2.5	7
65	Upper Extremity Deep Vein Thrombosis and Asymptomatic Vein Occlusion in Patients With Transvenous Leads: A Systematic Review and Meta-Analysis. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 698336.	2.4	7
66	The relation between body iron stores and adipose tissue function in patients with manifest vascular disease. <i>European Journal of Clinical Investigation</i> , 2013, 43, 1240-1249.	3.4	6
67	Impaired Cytoskeletal and Membrane Biophysical Properties of Acanthocytes in Hypobetalipoproteinemia â€ A Case Study. <i>Frontiers in Physiology</i> , 2021, 12, 638027.	2.8	6
68	Premature atherosclerosis, extremely low HDL-cholesterol and concurrent defects in APOA1 and ABCA1 genes: A family case report. <i>International Journal of Cardiology</i> , 2014, 177, e19-e21.	1.7	5
69	Association between bone metabolism regulators and arterial stiffness in type 2 diabetes patients. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2018, 28, 1245-1252.	2.6	5
70	Normal-range thyroid-stimulating hormone levels and cardiovascular events and mortality in type 2 diabetes. <i>Diabetes Research and Clinical Practice</i> , 2019, 157, 107880.	2.8	5
71	Apparent therapy-resistant hypertension as risk factor for the development of type 2 diabetes mellitus. <i>Journal of Hypertension</i> , 2020, 38, 45-51.	0.5	5
72	A Pathophysiological Perspective on the SARSâ€CoVâ€2 Coagulopathy. <i>HemaSphere</i> , 2020, 4, e457.	2.7	5

#	ARTICLE	IF	CITATIONS
73	Overcoming Obstacles in Lipid-lowering Therapy in Patients with HIV - A Systematic Review of Current Evidence. <i>AIDS Reviews</i> , 2019, 20, 205-219.	1.0	4
74	Variation in perioperative cerebral and hemodynamic monitoring during carotid endarterectomy. <i>Annals of Vascular Surgery</i> , 2021, 77, 153-163.	0.9	4
75	Effect modification in the association between glycated haemoglobin and cardiovascular disease and mortality in patients with type 2 diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2017, 19, 320-328.	4.4	3
76	Cost-effectiveness of magnetic resonance imaging for diagnosing recurrent ipsilateral deep vein thrombosis. <i>Blood Advances</i> , 2021, 5, 1369-1378.	5.2	3
77	Residual cardiovascular risk reduction guided by lifetime benefit estimation in patients with symptomatic atherosclerotic disease: effectiveness and cost-effectiveness. <i>European Journal of Preventive Cardiology</i> , 2021, , .	1.8	3
78	The ClearSight system for postoperative arterial blood pressure monitoring after carotid endarterectomy: a validation study. <i>American Journal of Hypertension</i> , 2021, , .	2.0	3
79	Research update for articles published in <sc>EJCI</sc> in 2011. <i>European Journal of Clinical Investigation</i> , 2013, 43, 1097-1110.	3.4	2
80	Relationship between recurrent miscarriage and early preterm delivery and recurrent events in patients with manifest vascular disease: The SMART study. <i>European Journal of Preventive Cardiology</i> , 2016, 23, 486-492.	1.8	2
81	Risk Factors for Recurrent Cardiovascular Events Before Age 65 Years or Within 2.5 Years of a Recent First Cardiovascular Event. <i>American Journal of Cardiology</i> , 2017, 120, 167-173.	1.6	2
82	2153The relation between systemic inflammation and incident cancer in patients with stable cardiovascular disease; a cohort study. <i>European Heart Journal</i> , 2019, 40, .	2.2	2
83	Development of a clinical decision tool to reduce diagnostic testing for primary aldosteronism in patients with difficult-to-control hypertension. <i>BMC Endocrine Disorders</i> , 2020, 20, 56.	2.2	2
84	Relationship between classic vascular risk factors and cumulative recurrent cardiovascular event burden in patients with clinically manifest vascular disease: results from the UCC-SMART prospective cohort study. <i>BMJ Open</i> , 2021, 11, e038881.	1.9	2
85	End-stage kidney disease in patients with clinically manifest vascular disease; incidence and risk factors: results from the UCC-SMART cohort study. <i>Journal of Nephrology</i> , 2021, 34, 1511-1520.	2.0	2
86	Pseudohypoparathyroidism mimicking cervical diffuse idiopathic skeletal hyperostosis with dysphagia: A case report and literature review. <i>Bone Reports</i> , 2021, 15, 101111.	0.4	2
87	Screen-detected abnormal ankle brachial index: A risk indicator for future cardiovascular morbidity and mortality in patients with manifest cardiovascular disease. <i>PLoS ONE</i> , 2022, 17, e0265050.	2.5	2
88	Lifestyle changes and kidney function: A 10-year follow-up study in patients with manifest cardiovascular disease. <i>European Journal of Clinical Investigation</i> , 2022, 52, e13814.	3.4	2
89	The Way to a Man's Stomach Is Through His Heart?. <i>Journal of the American College of Cardiology</i> , 2013, 62, 761-762.	2.8	1
90	Research update for articles published in <sc>EJCI</sc> in 2013. <i>European Journal of Clinical Investigation</i> , 2015, 45, 1005-1016.	3.4	1

#	ARTICLE	IF	CITATIONS
91	Letter by Westerink and Visseren Regarding Article, "Ezetimibe in Combination With Statins Ameliorates Endothelial Dysfunction in Coronary Arteries After Stenting: The CuVIC Trial (Effect of Tj ETQq1 1 0.784314 rgBT /Overlook Multicenter Randomized Controlled Trial" Arteriosclerosis, Thrombosis, and Vascular Biology, 2017, 27, 53.	2.4	1
92	2180 Estimating individual lifetime benefit and bleeding risk of adding rivaroxaban to aspirin for patients with stable cardiovascular disease: results from the COMPASS trial. European Heart Journal, 2019, 40, .	2.2	1
93	Bempedoic acid: Everything with a place and purpose. European Journal of Preventive Cardiology, 2020, , 2047487320929779.	1.8	1
94	The Impact of a Standardized Pre-visit Laboratory Testing Panel in the Internal Medicine Outpatient Clinic: a Controlled "On-Off" Trial. Journal of General Internal Medicine, 2021, 36, 1914-1920.	2.6	1
95	Comment on Vistisen et al. A Validated Prediction Model for End-Stage Kidney Disease in Type 1 Diabetes. Diabetes Care 2021;44:901-907. Diabetes Care, 2021, 44, e139-e139.	8.6	1
96	Estimating cardiovascular disease-free life-years with the addition of semaglutide in people with type 2 diabetes using pooled data from SUSTAIN 6 and PIONEER 6. European Heart Journal, 2020, 41, .	2.2	1
97	Impact of a Patient's Baseline Risk on the Relative Benefit and Harm of a Preventive Treatment Strategy: Applying Trial Results in Clinical Decision Making. Journal of the American Heart Association, 2022, 11, e017605.	3.7	1
98	The relation between body iron stores and adipose tissue function in patients with manifest vascular disease. European Journal of Clinical Investigation, 2015, 45, 1127-1127.	3.4	0
99	Response to Comment on Sharif et al. HDL Cholesterol as a Residual Risk Factor for Vascular Events and All-Cause Mortality in Patients With Type 2 Diabetes. Diabetes Care 2016;39:1424-1430. Diabetes Care, 2016, 39, e190-e191.	8.6	0
100	Reply to letter to the Editor "Bridging anticoagulation in patients with mechanical heart valves" International Journal of Cardiology, 2017, 236, 399.	1.7	0
101	114 Estimating individual cardiovascular disease risk reduction by blood pressure lowering in elderly patients: results from the HYVET study. European Heart Journal, 2018, 39, .	2.2	0
102	P4990 Heterogeneity of treatment effects from an intensive lifestyle weight loss intervention on cardiovascular events in patients with type 2 diabetes: data from the Look AHEAD trial. European Heart Journal, 2019, 40, .	2.2	0
103	P1540 Major adverse limb events (MALE) and the relation with classical risk factors in patients with symptomatic cardiovascular disease. European Heart Journal, 2019, 40, .	2.2	0
104	4943 Remnant cholesterol increases the risk for recurrent vascular events independent of LDL-cholesterol in patients with clinical manifest vascular disease. European Heart Journal, 2019, 40, .	2.2	0
105	Applicability of Blood Pressure-Lowering Drug Trials to Real-World Patients With Cardiovascular Disease. Hypertension, 2021, 77, 357-366.	2.7	0
106	FC 069 CHRONIC KIDNEY DISEASE AND ATRIAL FIBRILLATION: A DANGEROUS COMBINATION. Nephrology Dialysis Transplantation, 2021, 36, .	0.7	0
107	External applicability of SGLT2 inhibitor cardiovascular outcome trials to patients with type 2 diabetes and cardiovascular disease. Cardiovascular Diabetology, 2021, 20, 181.	6.8	0
108	Distribution of cardiovascular risk in type 2 diabetes: results of an analysis using data from the CAPTURE study. European Heart Journal, 2021, 42, .	2.2	0

#	ARTICLE	IF	CITATIONS
109	Redundant laboratory testing on referral from general practice to the outpatient clinic. BJGP Open, 2021, , BJGPO.2021.0134.	1.8	0
110	Prediction of 10-year and lifetime risk of cancer in individual patients with established cardiovascular disease, results from UCC-SMART and CANTOS. European Heart Journal, 2020, 41, .	2.2	0
111	External applicability of blood pressure-lowering drug trials to real-world patients with manifest cardiovascular disease. European Heart Journal, 2020, 41, .	2.2	0
112	Predicted lifetime therapy benefit guided treatment effectively reduces residual cardiovascular risk in patients with symptomatic atherosclerotic disease. European Heart Journal, 2020, 41, .	2.2	0